83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies "pure" IRAEs strongly associated with outcome in a phase I-II trial population. (December 2022)

Record Type:: Journal Article
Title:: 83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies "pure" IRAEs strongly associated with outcome in a phase I-II trial population. (December 2022)
Main Title:: 83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies "pure" IRAEs strongly associated with outcome in a phase I-II trial population
Authors:: Mazzarella, L.
Nicolo, E.
Esposito, A.
Crimini, E.
Tini, G.
Uliano, J.
Corti, C.
Trillo Aliaga, P.M.
Valenza, C.
Repetto, M.
Antonarelli, G.
Minchella, I.
Belli, C.
Locatelli, M.A.
Criscitiello, C.
Curigliano, G.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100187 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24744.xml